DAO and early-onset autosomal dominant Alzheimer disease: Indeed, when DAO inhibitors such as sodium benzoate have been used to treat schizophrenia (Lane et al., 2013; Tsai et al., 1998) and early-stage Alzheimer’s disease (Lin et al., 2014) they have been found to produce improvements in neurocognitive functioning, as an adjunct to improvements in symptoms of clinical pathology.